Sara Abbasigharaei, Aysegul Bostanci, Kiana Tabari, Mahmut Cerkez Ergoren
{"title":"通过定量分析北塞浦路斯人群中SMN1缺失的SMA携带者频率。","authors":"Sara Abbasigharaei, Aysegul Bostanci, Kiana Tabari, Mahmut Cerkez Ergoren","doi":"10.18071/isz.78.0349","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>Spinal muscular atrophy (SMA) is a rare autosomal recessive neuromuscular disorder, affecting approximately one out of 10,000 live births. Muscular atrophy is caused by the gradual loss of alpha motor neurons within the ventral spinal cord or motor nuclei in the lower brainstem. In this study, we aimed to evaluate the carrier frequency of SMN1 gene mutation causing SMA in the Turkish Cypriot population.</p><p><strong>Methods: </strong>This is the first study to evaluate the SMN1 deletion mutations in this population. Exon 7 and 8 deletions of the SMN1 gene, and c.849C/T substitution within exon 7 were detected by Quantitative Real-Time PCR (RT-qPCR) method.</p><p><strong>Results: </strong>In a total of 100 individuals, 3 patients turned out to be carriers of the pathogenic SMN1 gene variant in both exon 7 and 8 (carrier status type 1) and another patient (Carrier status type 2) showed a car- rier status of SMN1 gene only in exon 7. Our findings revealed that the carrier frequency of mutation in the SMN1 gene exon 7 is 4% (4:100 healthy individuals) while for exon 8 is 3% (3:100 healthy individuals). In conclusion, health precautions must be taken due to the high frequency of SMA linked to the deletion of the SMN1 gene.</p><p><strong>Conclusion: </strong>Carrier testing as a technique for genetic counseling may be advantageous for individuals with a positive family history or can even be a useful test in a society with a high prevalence of this disease. For this population, we strongly recommend prenatal testing. The Ministry of Health has received our findings, and they will decide whether to include tests for the SMN1 gene variant in premarital examinations.</p>","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"78 9-10","pages":"349-355"},"PeriodicalIF":0.6000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Carrier frequency of SMA by quantitative analysis of the SMN1 deletion in the Northern-Cyprus population.\",\"authors\":\"Sara Abbasigharaei, Aysegul Bostanci, Kiana Tabari, Mahmut Cerkez Ergoren\",\"doi\":\"10.18071/isz.78.0349\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and purpose: </strong>Spinal muscular atrophy (SMA) is a rare autosomal recessive neuromuscular disorder, affecting approximately one out of 10,000 live births. Muscular atrophy is caused by the gradual loss of alpha motor neurons within the ventral spinal cord or motor nuclei in the lower brainstem. In this study, we aimed to evaluate the carrier frequency of SMN1 gene mutation causing SMA in the Turkish Cypriot population.</p><p><strong>Methods: </strong>This is the first study to evaluate the SMN1 deletion mutations in this population. Exon 7 and 8 deletions of the SMN1 gene, and c.849C/T substitution within exon 7 were detected by Quantitative Real-Time PCR (RT-qPCR) method.</p><p><strong>Results: </strong>In a total of 100 individuals, 3 patients turned out to be carriers of the pathogenic SMN1 gene variant in both exon 7 and 8 (carrier status type 1) and another patient (Carrier status type 2) showed a car- rier status of SMN1 gene only in exon 7. Our findings revealed that the carrier frequency of mutation in the SMN1 gene exon 7 is 4% (4:100 healthy individuals) while for exon 8 is 3% (3:100 healthy individuals). In conclusion, health precautions must be taken due to the high frequency of SMA linked to the deletion of the SMN1 gene.</p><p><strong>Conclusion: </strong>Carrier testing as a technique for genetic counseling may be advantageous for individuals with a positive family history or can even be a useful test in a society with a high prevalence of this disease. For this population, we strongly recommend prenatal testing. The Ministry of Health has received our findings, and they will decide whether to include tests for the SMN1 gene variant in premarital examinations.</p>\",\"PeriodicalId\":50394,\"journal\":{\"name\":\"Ideggyogyaszati Szemle-Clinical Neuroscience\",\"volume\":\"78 9-10\",\"pages\":\"349-355\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2025-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ideggyogyaszati Szemle-Clinical Neuroscience\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.18071/isz.78.0349\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ideggyogyaszati Szemle-Clinical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18071/isz.78.0349","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Carrier frequency of SMA by quantitative analysis of the SMN1 deletion in the Northern-Cyprus population.
Background and purpose: Spinal muscular atrophy (SMA) is a rare autosomal recessive neuromuscular disorder, affecting approximately one out of 10,000 live births. Muscular atrophy is caused by the gradual loss of alpha motor neurons within the ventral spinal cord or motor nuclei in the lower brainstem. In this study, we aimed to evaluate the carrier frequency of SMN1 gene mutation causing SMA in the Turkish Cypriot population.
Methods: This is the first study to evaluate the SMN1 deletion mutations in this population. Exon 7 and 8 deletions of the SMN1 gene, and c.849C/T substitution within exon 7 were detected by Quantitative Real-Time PCR (RT-qPCR) method.
Results: In a total of 100 individuals, 3 patients turned out to be carriers of the pathogenic SMN1 gene variant in both exon 7 and 8 (carrier status type 1) and another patient (Carrier status type 2) showed a car- rier status of SMN1 gene only in exon 7. Our findings revealed that the carrier frequency of mutation in the SMN1 gene exon 7 is 4% (4:100 healthy individuals) while for exon 8 is 3% (3:100 healthy individuals). In conclusion, health precautions must be taken due to the high frequency of SMA linked to the deletion of the SMN1 gene.
Conclusion: Carrier testing as a technique for genetic counseling may be advantageous for individuals with a positive family history or can even be a useful test in a society with a high prevalence of this disease. For this population, we strongly recommend prenatal testing. The Ministry of Health has received our findings, and they will decide whether to include tests for the SMN1 gene variant in premarital examinations.
期刊介绍:
The aim of Clinical Neuroscience (Ideggyógyászati Szemle) is to provide a forum for the exchange of clinical and scientific information for a multidisciplinary community. The Clinical Neuroscience will be of primary interest to neurologists, neurosurgeons, psychiatrist and clinical specialized psycholigists, neuroradiologists and clinical neurophysiologists, but original works in basic or computer science, epidemiology, pharmacology, etc., relating to the clinical practice with involvement of the central nervous system are also welcome.